An official website of the United States government
Dengue Vaccine Recommendations
Sanofi-Pasteur will stop manufacturing its dengue vaccine for children. The manufacturer is discontinuing the vaccine citing a lack of demand in the global market to continue production of this vaccine. CDC, in collaboration with the Puerto Rico Department of Health, will continue alerting health professionals about the discontinuation of Dengvaxia and the use of this vaccine as recommended by the Advisory Committee on Immunization Practices (ACIP). Dengvaxia is safe and effective when administered as recommended. There are two other dengue vaccines either approved or in late stages of development. However, they are not currently available in the United States. People can continue to protect themselves and their families from dengue by preventing mosquito bites and controlling mosquitoes in and around their homes.
Below are summaries of recommendations from CDC’s Advisory Committee on Immunization Practices (ACIP). For the full text of the recommendations, see Dengue Vaccine: Recommendations of the Advisory Committee on Immunization Practices, United States, 2021.
Dengue vaccine is recommended for adolescents who are:
- 9–16 years old
- Live in areas where dengue occurs frequently or continuously including:
- American Samoa
- Puerto Rico
- U.S. Virgin Islands
- Federated States of Micronesia
- Republic of Marshall Islands
- Republic of Palau
- Have laboratory-confirmed evidence of previous dengue infection including:
- Positive dengue RT-PCR test result, or
- Positive dengue NS1 antigen test result, or
- Positive results on a pre-vaccination screening dengue virus IgG testing process meeting specific performance standards
- For more information, see Laboratory Testing Requirements for Vaccination with Dengvaxia Dengue Vaccine.
Contraindications and Precautions
Do not administer dengue vaccines to
- A person who lacks laboratory evidence of previous dengue infection
- A person who has ever had a severe allergic reaction (e.g., anaphylaxis) after a previous dose of this vaccine
- A person who has a severe allergy to any vaccine component (see the Dengvaxia package insert)
- A person with severe immunodeficiency or immunosuppression due to underlying disease or therapy, including persons with symptomatic HIV infection or CD4+ T-lymphocyte count of <200/mm3.
- A person who lacks laboratory evidence of a previous dengue infection
Healthcare providers should weigh the risks of vaccination against the risk for dengue for the following populations:
- Pregnant women
- Breastfeeding women
- Persons with HIV infection
- Persons with moderate or severe acute illness with or without fever